Nugenerex Immuno-oncology, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Nugenerex Immuno-oncology, Inc. reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $5.07 million for the 9-month period ending 2021-04-30, per its 10-Q filed 2021-06-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-06-14
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-04-30 was $1.74M, a 1860.99% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-01-31 was $1.81M, a 2073.25% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-10-31 was $1.52M, a 436.01% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-07-31 was $277.74K.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $733.31K, a 87.02% increase from fiscal 2019.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $392.11K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2021-04-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $3.55M derived: sum of 2 quarters · filed 2021-06-14 | $5.07M 10-Q · filed 2021-06-14 | $5.35M derived: sum of 4 quarters · filed 2021-06-14 |
| 2021-01-31 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-12 | $3.33M 10-Q · filed 2021-03-12 | $3.61M derived: sum of 3 quarters · filed 2021-03-12 | $3.70M derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-10-31 | $1.52M 10-Q · filed 2020-12-15 | $1.80M derived: sum of 2 quarters · filed 2020-12-15 | $1.89M derived: sum of 3 quarters · filed 2021-06-14 | $1.97M derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-07-31 | $277.74K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | $366.40K derived: sum of 2 quarters · filed 2021-06-14 | $449.79K derived: sum of 3 quarters · filed 2021-06-14 | $733.31K 10-K · filed 2020-10-29 |
| 2020-04-30 | $88.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $172.05K derived: sum of 2 quarters · filed 2021-06-14 | $455.57K 10-Q · filed 2021-06-14 | |
| 2020-01-31 | $83.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-12 | $366.90K 10-Q · filed 2021-03-12 | ||
| 2019-10-31 | $283.52K 10-Q · filed 2020-12-15 | |||
| 2019-07-31 | $392.11K 10-K · filed 2020-10-29 |